Last reviewed · How we verify
NCT04648813
Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses
Phase 4 trial testing tiotropium bromide monohydrate (Spiriva Respimat) in Allergic Asthma in 15 participants. Completed in 20 April 2021.
20 April 2021
Quick facts
| Lead sponsor | University of Saskatchewan |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 13 November 2020 |
| Primary completion | 20 April 2021 |
| Estimated completion | 20 April 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- tiotropium bromide monohydrate (Spiriva Respimat)
- matching placebo — full drug profile →
Conditions studied
- Allergic Asthma — all drugs for Allergic Asthma →
Sponsor
University of Saskatchewan
Who can join
Adults 18 to 65, any sex, with Allergic Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will compare the effect of inhaled tiotropium versus placebo on allergen induced early asthmatic responses in individuals with atopic asthma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04648813
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Allergic Asthma
Currently open trials in the same condition.
- NCT07055542 — Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study · NA · recruiting
- NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
- NCT07342803 — Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients · Phase 2 · recruiting
- NCT06438757 — Trial of JYB1904 in Patients With Allergic Asthma · Phase 2 · active not recruiting
- NCT06771934 — Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma · active not recruiting
Other University of Saskatchewan trials
Trials by the same sponsor.
- NCT07433686 — Saskatoon Berry Juice for Muscle Recovery · NA · not yet recruiting
- NCT07489469 — Effectiveness of an AI Scribe Compared to Routine Templates for Clinical Documentation in Orthopedic Consultations · NA · completed
- NCT06946316 — Dairy vs Plant-based Beverages for Improving Bone Health During Exercise · NA · recruiting
- NCT04276857 — Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer · NA · recruiting
- NCT03401294 — Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04648813 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Saskatchewan
- Last refreshed: 30 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04648813.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing